Transgene receives FDA IND Clearance for Lead myvac™ Individualized Immunotherapy, TG4050, to Commence Clinical Development in Ovarian Cancer

Business Wire Health: Clinical Trials Ne.. - 17m ago Preview

 
 
• AUTO POST
 
• SAVE TO EVERNOTE

STRASBOURG, France--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/TG4050?src=hash" target="_blank"gt;#TG4050lt;/agt;--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of solid tumors, today announces that it has received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) to proceed with a Phase 1 clinical trial of its lead myvac™ candidate TG4050 as a potential treatment for ovarian cancer patients after first-line surgery and chemotherapy. TG4050